GMED Long Call Strategy
GMED (Globus Medical, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
GMED (Globus Medical, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $10.19B, a trailing P/E of 17.43, a beta of 1.00 versus the broader market, a 52-week range of 51.79-101.4, average daily share volume of 1.2M, a public-listing history dating back to 2012, approximately 5K full-time employees. These structural characteristics shape how GMED stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.00 places GMED roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long call on GMED?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current GMED snapshot
As of May 15, 2026, spot at $76.44, ATM IV 32.80%, IV rank 16.68%, expected move 9.40%. The long call on GMED below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on GMED specifically: GMED IV at 32.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a GMED long call, with a market-implied 1-standard-deviation move of approximately 9.40% (roughly $7.19 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GMED expiries trade a higher absolute premium for lower per-day decay. Position sizing on GMED should anchor to the underlying notional of $76.44 per share and to the trader's directional view on GMED stock.
GMED long call setup
The GMED long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GMED near $76.44, the first option leg uses a $77.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GMED chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GMED shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $77.50 | $2.60 |
GMED long call risk and reward
- Net Premium / Debit
- -$260.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$260.00
- Breakeven(s)
- $80.10
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
GMED long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on GMED. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$260.00 |
| $16.91 | -77.9% | -$260.00 |
| $33.81 | -55.8% | -$260.00 |
| $50.71 | -33.7% | -$260.00 |
| $67.61 | -11.6% | -$260.00 |
| $84.51 | +10.6% | +$441.10 |
| $101.41 | +32.7% | +$2,131.12 |
| $118.31 | +54.8% | +$3,821.14 |
| $135.21 | +76.9% | +$5,511.16 |
| $152.11 | +99.0% | +$7,201.18 |
When traders use long call on GMED
Long calls on GMED express a bullish thesis with defined risk; traders use them ahead of GMED catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
GMED thesis for this long call
The market-implied 1-standard-deviation range for GMED extends from approximately $69.25 on the downside to $83.63 on the upside. A GMED long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current GMED IV rank near 16.68% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on GMED at 32.80%. As a Healthcare name, GMED options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GMED-specific events.
GMED long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GMED positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GMED alongside the broader basket even when GMED-specific fundamentals are unchanged. Long-premium structures like a long call on GMED are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current GMED chain quotes before placing a trade.
Frequently asked questions
- What is a long call on GMED?
- A long call on GMED is the long call strategy applied to GMED (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With GMED stock trading near $76.44, the strikes shown on this page are snapped to the nearest listed GMED chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are GMED long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the GMED long call priced from the end-of-day chain at a 30-day expiry (ATM IV 32.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$260.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a GMED long call?
- The breakeven for the GMED long call priced on this page is roughly $80.10 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current GMED market-implied 1-standard-deviation expected move is approximately 9.40%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on GMED?
- Long calls on GMED express a bullish thesis with defined risk; traders use them ahead of GMED catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current GMED implied volatility affect this long call?
- GMED ATM IV is at 32.80% with IV rank near 16.68%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.